Design Therapeutics (DSGN) Assets Average (2021 - 2026)

Design Therapeutics has disclosed Assets Average across 6 years of filings, most recently posting $228.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $228.3 million, down 6.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $228.3 million (down 6.72% YoY), and the FY2025 annual result was $239.1 million, down 11.71% from the prior year.
• Assets Average came in at $228.3 million for Q1 2026 at Design Therapeutics, up from $219.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $384.7 million in Q1 2022 to a low of $217.3 million in Q3 2025.
• The 5-year median for Assets Average is $284.2 million (2024), against an average of $290.5 million.
• Across the five-year window, Assets Average surged 71.59% in 2022 and declined 18.18% in 2025, its largest moves.
• Design Therapeutics' Assets Average stood at $347.9 million in 2022, then retreated by 15.26% to $294.8 million in 2023, then fell by 12.86% to $256.9 million in 2024, then slipped by 14.75% to $219.0 million in 2025, then climbed by 4.26% to $228.3 million in 2026.
• The last three Assets Average figures came in at $228.3 million (Q1 2026), $219.0 million (Q4 2025), and $217.3 million (Q3 2025), per Business Quant data.